Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
S.-Y. Liu
Institution:
Guangdong Provincial People's Hospital
Observed institutions:
Guangdong Academy of Medical Sciences,
Guangdong Provincial People's Hospital
OpenAlex ID:
A5091592097
A comprehensive model of genetic-features predicts outcome of personalized adjuvant treatment in resected EGFR-mutant stage II-IIIA NSCLC: Results from a phase III trial (CTONG 1104-ADJUVANT)
2019
·
Y.-L. Wu
, S.-Y. Liu
, et al.
·
Annals of Oncology
·
5
PDF
LBA2 Phase II study of PD-L1 expression guidance on neoadjuvant (NA) nivolumab (Nivo) monotherapy with or without platinum-doublet chemotherapy in resectable NSCLC
2022
·
S.-Y. Liu
, S. Dong
, et al.
·
Immuno-Oncology Technology
·
3
P1.27-03 Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis
2023
·
C. Zhang
, D.-C. Yi
, et al.
·
Journal of Thoracic Oncology
·
1
PDF
Show more works
View as search
Works count:
3
Citation count:
9
H-index:
2
I10-index:
Year
Topic
Type